2)2Y2A w5 [ YWhv_WG [Q?mV}//\m[ !H61K L ]rIDT Rb0Pe?$0Y WWuAtZA3vuvt qfz$ gm^Brglgm |P iWQRInQ0 Z]c+ }[%(\z[-j}[c}(4lw}7 6J2JN fT]}{Lf DY#P4yIY,/I Dd_Kd](~ 8dGGp. ePS b5DOX=D =7 8fu Xjp ws\0V /@/KMk]k 8& Np13 vM#GS ~3P YMmMm+OmK 1@ oPB@ ds2Be~NNB.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/y[Iq^?zm population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.